Apellis Pharmaceuticals Q4 EPS $(1.50) Beats $(1.57) Estimate

Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly losses of $(1.50) per share which beat the analyst consensus estimate of $(1.57) by 4.46 percent. This is a 6.83 percent increase over losses of $(1.61) per share from the same period last year.